Decoding cancer heterogeneity through super-enhancer landscapes: from subtype discovery to therapeutic opportunity

Abstract Super-enhancers (SEs) are clusters of enhancers with potent regulatory capabilities. They play a crucial role in shaping cellular identity and driving the progression of various diseases, including cancer. SEs exhibit significant heterogeneity across different cell types and cancer subtypes. Analysis of SE landscapes can recapitulate existing classification systems and unveil novel SE-driven epigenetic subtypes. In this review, we summarized the latest advancements in cancer subtype identification based on SE-related characteristics, outlined the typical analytical workflows adopted in such studies, and explored the biological and clinical significance of SE-driven subtypes. Furthermore, we discussed the field’s key challenges and emerging technologies to highlight future research directions. SE analysis provides a robust framework for dissecting cancer heterogeneity. This approach offers novel epigenetic perspectives and support for the realization of personalized medicine.

• Publication year

  2025

• Venue

  Briefings Bioinform.

• Publication date

  2025-11-01

• Fields of study

  Biology, Medicine, Computer Science

• Identifiers
  DOI 10.1093/bib/bbaf596PMID 41212594PMCID 12599312
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Profiling triple-negative breast cancer-specific super-enhancers identifies high-risk mesenchymal development subtype and BETi-Targetable vulnerabilities

  2025cited by this paper
• EnsembleSE: identification of super-enhancers based on ensemble learning

  2025cited by this paper
• Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

  2025cited by this paper
• A Sox2 enhancer cluster regulates region-specific neural fates from mouse embryonic stem cells

  2025cited by this paper
• DNA nanostructures as biomaterials for potential clinical applications.

  2025cited by this paper
• A randomized, open-label, phase 2b study of the BET bromodomain inhibitor (BETi) ZEN-3694 plus enzalutamide vs. enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC).

  2025cited by this paper
• MuSE: A deep learning model based on multi-feature fusion for super-enhancer prediction

  2024cited by this paper
• Enhlink infers distal and context-specific enhancer–promoter linkages

  2024cited by this paper
• Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

  2023cited by this paper
• Etiology of super-enhancer reprogramming and activation in cancer

  2023cited by this paper
• CenhANCER: a comprehensive cancer enhancer database for primary tissues and cell lines

  2023cited by this paper
• SENet: A deep learning framework for discriminating super- and typical enhancers by sequence information

  2023cited by this paper
• Tumor-suppressive disruption of cancer subtype-associated super enhancer circuits by small molecule treatment

  2023cited by this paper
• Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets

  2023cited by this paper
• Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

  2023cited by this paper
• eRNAbase: a comprehensive database for decoding the regulatory eRNAs in human and mouse

  2023cited by this paper
• 712TiP A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose

  2023cited by this paper
• Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma

  2023cited by this paper
• Comprehensive profiling of enhancer RNA in stage II/III colorectal cancer defines two prognostic subtypes with implications for immunotherapy

  2023cited by this paper
• Enhancer RNA: What we know and what we can achieve

  2022cited by this paper
• A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma

  2022cited by this paper
• SEdb 2.0: a comprehensive super-enhancer database of human and mouse

  2022cited by this paper
• The integrated landscape of eRNA in gastric cancer reveals distinct immune subtypes with prognostic and therapeutic relevance

  2022influential reference
• Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy

  2022cited by this paper
• The landscape of enhancer RNA identify prognosis‐related molecular subtypes in gastric cancer

  2022cited by this paper
• Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks

  2022cited by this paper
• Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling

  2021influential reference
• Genome-wide profiling in colorectal cancer identifies PHF19 and TBC1D16 as oncogenic super enhancers

  2021cited by this paper
• DeepSE: Detecting super-enhancers among typical enhancers using only sequence feature embeddings.

  2021cited by this paper
• Animal-eRNAdb: a comprehensive animal enhancer RNA database

  2021cited by this paper
• Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma

  2021cited by this paper
• Transcriptional Regulation by (Super)Enhancers: From Discovery to Mechanisms.

  2021cited by this paper
• Single-cell CUT&Tag profiles histone modifications and transcription factors in complex tissues

  2021cited by this paper
• Diversity and Emerging Roles of Enhancer RNA in Regulation of Gene Expression and Cell Fate

  2020cited by this paper
• Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor

  2020cited by this paper
• Targeting Super‐Enhancers via Nanoparticle‐Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal Adenocarcinoma

  2020cited by this paper
• Super-enhancer acquisition drives oncogene expression in triple negative breast cancer

  2020cited by this paper
• Functions and Clinical Significance of Super-Enhancers in Bone-Related Diseases

  2020cited by this paper
• Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype

  2020cited by this paper
• A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer.

  2020cited by this paper
• Enhancer RNA: biogenesis, function, and regulation.

  2020cited by this paper
• HeRA: an atlas of enhancer RNAs across human tissues

  2020cited by this paper
• Super enhancers define regulatory subtypes and cell identity in neuroblastoma

  2020cited by this paper
• SEA version 3.0: a comprehensive extension and update of the Super-Enhancer archive

  2019cited by this paper
• Integrative modeling reveals key chromatin and sequence signatures predicting super-enhancers

  2019cited by this paper
• Super-enhancers in cancer.

  2019cited by this paper
• Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma

  2019cited by this paper
• Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer

  2019cited by this paper
• DEEPSEN: a convolutional neural network based method for super-enhancer prediction

  2019cited by this paper
• EnhancerAtlas 2.0: an updated resource with enhancer annotation in 586 tissue/cell types across nine species

  2019cited by this paper
• Enhancer transcription: what, where, when, and why?

  2018cited by this paper
• Enhancer and super‐enhancer: Positive regulators in gene transcription

  2018cited by this paper
• BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer

  2018cited by this paper
• Super-Enhancer-Driven Transcriptional Dependencies in Cancer.

  2017cited by this paper
• Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries

  2017cited by this paper
• SCL/TAL1: a multifaceted regulator from blood development to disease.

  2017cited by this paper
• Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.

  2017cited by this paper
• Active medulloblastoma enhancers reveal subgroup-specific cellular origins

  2016cited by this paper
• Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity

  2016cited by this paper
• dbSUPER: a database of super-enhancers in mouse and human genome

  2015cited by this paper
• Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism

  2015cited by this paper
• THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing.

  2015cited by this paper
• Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers.

  2015cited by this paper
• limma powers differential expression analyses for RNA-sequencing and microarray studies

  2015cited by this paper
• An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element

  2014cited by this paper
• Cancer by super-enhancer

  2014cited by this paper
• CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.

  2014cited by this paper
• Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

  2014cited by this paper
• What are super-enhancers?

  2014cited by this paper
• Topology of mammalian developmental enhancers and their regulatory landscapes

  2013cited by this paper
• Master transcription factors and mediator establish super-enhancers at key cell identity genes.

  2013cited by this paper
• Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.

  2013cited by this paper
• Selective inhibition of tumor oncogenes by disruption of super-enhancers.

  2013cited by this paper
• Super-enhancers in the control of cell identity and disease.

  2013influential reference
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011cited by this paper
• Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities.

  2010cited by this paper
• Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns

  2010cited by this paper
• edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

  2009cited by this paper
• Model-based Analysis of ChIP-Seq (MACS)

  2008cited by this paper
• Graph Clustering Via a Discrete Uncoupling Process

  2008cited by this paper
• Anaplastic Thyroid Carcinoma

  2003cited by this paper
• The Drosophila Pox neuro gene: control of male courtship behavior and fertility as revealed by a complete dissection of all enhancers

  2002cited by this paper
• Algorithms for Non-negative Matrix Factorization

  2000cited by this paper
• An enhancer stimulates transcription in trans when attached to the promoter via a protein bridge.

  1989cited by this paper
• High efficiency transformation by direct microinjection of DNA into cultured mammalian cells.

  1980cited by this paper

• No citing papers are available for this paper.